Description
CJC-1295 and Ipamorelin are synthetic peptides widely studied in laboratory research focused on somatotropic axis regulation and growth hormone–related signaling pathways. This dual-peptide formulation serves as a research tool for examining coordinated receptor-mediated endocrine mechanisms.
Biochemical Characteristics
CJC-1295 is a GHRH analog designed to stimulate growth hormone receptor signaling, while Ipamorelin selectively activates the growth hormone secretagogue receptor (GHS-R1a). Together, these peptides support experimental evaluation of complementary receptor interactions and intracellular signaling dynamics.
Research Applications
This peptide combination is utilized in research models investigating growth hormone regulation, receptor activation kinetics, peptide stability, and endocrine feedback mechanisms under controlled laboratory conditions.
Pathway / Mechanistic Context
Mechanistic research focuses on activation of GHRH and GHS-R1a receptors and downstream signaling cascades, including JAK-STAT and calcium-mediated pathways influencing somatotropic axis modulation.
Preclinical Research Summary
Preclinical investigations have evaluated CJC-1295 and Ipamorelin in in vitro and experimental models to better understand coordinated receptor signaling and growth hormone pathway dynamics.
Form & Analytical Testing
CJC-1295 and Ipamorelin are supplied as lyophilized peptides and undergo analytical verification, including HPLC testing, to confirm identity, purity, and composition consistency for laboratory research use.
RUO Disclaimer
This product is intended strictly for research and laboratory use only. It is not approved for human consumption, medical treatment, veterinary use, cosmetic application, or diagnostic purposes. Handling should be performed only by qualified professionals trained in proper laboratory procedures.





Reviews
There are no reviews yet.